Brain Repair
Ibogaine treatment for brain repair
Most of what ibogaine is known for is addiction. The newer and more surprising line of research is what it appears to do to injured brain tissue itself. Four pages sit under this one, and the honest position differs sharply between them.
What “brain repair” actually means here
The brain does not heal the way a bone does. After an injury, an inflammatory process runs on far longer than it should, connections between regions fall out of time with each other, and the cortex can thin in the places that took the load. Most treatment on offer manages the symptoms that produces. Very little of it claims to touch the underlying tissue.
The reason ibogaine keeps coming up in this context is a proposed neurotrophic mechanism: in animal and cell studies it increases growth factors that push neurons to repair and reconnect, most consistently GDNF, and BDNF depending on context.¹⁷ What moved it from theory to something worth writing about is that researchers finally scanned people before and after.⁴³
Below are the four pages people ask us for. We have put the strength of the evidence on the face of each one rather than letting the strongest result stand in for all of them.
Not sure which of these describes you
Most people arrive here after a head injury, or a diagnosis, or years of both. The consultation exists to work out whether ibogaine is a reasonable thing to consider in your case, and to tell you when it is not. Cardiac screening comes before anything else, and it rules some people out.
Citations (4)
[17] Marton S, González B, Rodríguez-Bottero S, et al. (2019). Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology, 10, 193. Read the source →
Rodent study showing that a single dose of ibogaine raises BDNF expression in the nucleus accumbens, substantia nigra, and prefrontal cortex, and selectively raises GDNF in the ventral tegmental area at the dose range effective in self-administration models.
[42] Cherian K, Keynan J, Anker L, Faerman A, Brown R, Shamma A, Keynan O, Coetzee J, Batail JM, Phillips A, Bassano N, Sahlem G, Inzunza J, Millar T, Dickinson J, Rolle C, Keller J, Adamson M, Kratter I, Williams N (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30, 373–381. Read the source →
The MISTIC trial. 30 male US Special Operations Forces veterans with predominantly mild traumatic brain injury received intravenous magnesium plus oral ibogaine (mean 12.1 mg/kg); 23 met criteria for PTSD at baseline. One month after treatment the group had moved from mild-to-moderate disability to no disability on the WHODAS-2.0 (30.2 to 5.1, d = 2.20), the study primary outcome. PTSD symptoms fell 88% on average, with a 100% response rate and 86% remission (d = 2.54); depression fell 87% (83% remission) and anxiety 81% (83% remission). Suicidal ideation fell from 47% at baseline to 7% at one month. Participants also gained in processing speed, executive function, verbal fluency and verbal learning, with no cognitive decline on any measure, and there were no serious or unexpected treatment-emergent adverse events. Open-label and uncontrolled, in a highly selected cohort, with magnesium co-administered, so the effect cannot be attributed to ibogaine alone.
[43] Adamson M (2025). Changes in Brain Structure and Age in Veterans With TBI After Treatment With Magnesium-Ibogaine. Archives of Physical Medicine and Rehabilitation, 106(4), e162–e163. Read the source →
The first in-human structural MRI evidence of brain change after ibogaine. In the same 30 MISTIC veterans, cortical thickness increased significantly in 11 of 13 regions of interest at roughly 7 days post-treatment and was sustained at one month, and predicted brain age fell by 1.60 years at one month (d = 1.035, p = 0.0082). The authors describe the findings as consistent with a proposed neurotrophic mechanism, not as confirmation of one.
[50] Chen DQ, et al. (2025). Neurorestorative effects of ibogaine in multiple sclerosis: serial MRI findings in two patients. Frontiers in Immunology. Read the source →
The first published neuroimaging data on ibogaine in multiple sclerosis. Two patients underwent serial MRI. One, a 41-year-old man with relapsing-remitting MS, showed a 70% reduction in lesion volume (1,609.8 to 480.5 mm3) at three months, with diffusion changes consistent with remyelination and reduced inflammation. The second, a 44-year-old woman with secondary progressive MS, showed cortical and subcortical changes. Two patients, one clinic, unblinded and uncontrolled: a first signal, not a result.
Let’s connect.
No pressure. Tell us a little about what you’re going through.